Literature DB >> 6409316

Mass vaccination programme aimed at eradicating measles, mumps, and rubella in Sweden: first experience.

B Christenson, M Böttiger, L Heller.   

Abstract

General vaccination with a combined measles, mumps, and rubella vaccine was introduced in Sweden in 1982. The immunisation schedule comprises two vaccine injections, given at 18 months and 12 years of age, respectively. A controlled field study was carried out in 150 children aged 18 months using two different batches of the vaccine. Seroconversion was seen in 96% against measles, 93% against mumps, and 99% against rubella--the same rates with both vaccine lots. Nevertheless, a difference was noted between the two batches with respect to postvaccination reactions. Fever and rash were recorded mainly five to 12 days after vaccination. Moderate fever (38.5-39.4 degrees C) was observed in 22 children, high fever (greater than or equal to 39.5 degrees C) in 33, and rash in 35. Preliminary results obtained by follow up of routinely vaccinated schoolchildren aged 12 indicated considerably lower rates of fever and rash during the postvaccination period, occurring in 3-10% of cases only. These findings show that complete eradication of measles, mumps, and rubella in Sweden is entirely practicable by the mass vaccination programme and that side effects of vaccination are likely to be few and mild.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6409316      PMCID: PMC1548959          DOI: 10.1136/bmj.287.6389.389

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  6 in total

1.  Hemolysis-in-gel test for the demonstration of antibodies to rubella virus.

Authors:  O Strannegård; L Grillner; I M Lindberg
Journal:  J Clin Microbiol       Date:  1975-06       Impact factor: 5.948

2.  Live attenuated mumps virus vaccine. 1. Vaccine development.

Authors:  E B Buynak; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1966-12

3.  Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies.

Authors:  J Stokes; R E Weibel; V M Villarejos; J A Arguedas; E B Buynak; M R Hilleman
Journal:  JAMA       Date:  1971-10-04       Impact factor: 56.272

4.  Microneutralization test for the determination of mumps antibody in vero cells.

Authors:  M T Kenny; K L Albright; R P Sanderson
Journal:  Appl Microbiol       Date:  1970-09

5.  Combined live measles, mumps, and rubella virus vaccines.

Authors:  E B Buynak; R E Weibel; J E Whitman; J Stokes; M R Hilleman
Journal:  JAMA       Date:  1969-03-24       Impact factor: 56.272

6.  Vaccination programme for eradication of measles, mumps, and rubella.

Authors:  J Taranger
Journal:  Lancet       Date:  1982-04-17       Impact factor: 79.321

  6 in total
  11 in total

1.  Measles, mumps, and rubella vaccination.

Authors:  A Hill
Journal:  BMJ       Date:  1992-03-21

2.  Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation.

Authors:  Hiroto Inaba; Christine M Hartford; Deqing Pei; Meredith J Posner; Jie Yang; Randall T Hayden; Ashok Srinivasan; Brandon M Triplett; Jon A McCulllers; Ching-Hon Pui; Wing Leung
Journal:  Br J Haematol       Date:  2011-10-24       Impact factor: 6.998

3.  Seroepidemiology of measles in Catalonia (Spain) 1985-1986.

Authors:  L Salleras; J Vidal; J Canela; M T Jimenez De Anta; T Pumarola; J J Coll; M L De La Puente; L Serra
Journal:  Eur J Epidemiol       Date:  1990-06       Impact factor: 8.082

Review 4.  Boxing and the brain.

Authors:  J A Corsellis
Journal:  BMJ       Date:  1989-01-14

5.  Measles, mumps, and rubella: the need for a change in immunisation policy.

Authors:  D Walker; H Carter; I G Jones
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-07

6.  Serological evaluation of a measles, mumps, and rubella vaccine.

Authors:  C M Robertson; V J Bennett; N Jefferson; R T Mayon-White
Journal:  Arch Dis Child       Date:  1988-06       Impact factor: 3.791

7.  Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months.

Authors:  G De Serres; N Boulianne; F Meyer; B J Ward
Journal:  Epidemiol Infect       Date:  1995-10       Impact factor: 2.451

8.  Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.

Authors:  T R Coté; D Sivertson; J M Horan; M L Lindegren; D M Dwyer
Journal:  Public Health Rep       Date:  1993 Jul-Aug       Impact factor: 2.792

9.  Chapter 8 Paramyxoviruses.

Authors: 
Journal:  Perspect Med Virol       Date:  2008-05-29

10.  Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella.

Authors:  M Böttiger; B Christenson; V Romanus; J Taranger; A Strandell
Journal:  Br Med J (Clin Res Ed)       Date:  1987-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.